Welcome to our dedicated page for Compugen SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Compugen’s biotech disclosures can feel like decoding lab notebooks—clinical trial protocols, milestone payments from AstraZeneca, and shifting R&D burn all sit deep inside each form. If you have ever searched for "Compugen insider trading Form 4 transactions" or wondered which study update triggered the last 8-K, you know the challenge.
Stock Titan solves that problem instantly. Our AI-powered summaries strip away jargon so "understanding Compugen SEC documents with AI" is no longer a wish—it’s a click. Need the "Compugen quarterly earnings report 10-Q filing"? We surface cash-runway tables and collaboration revenue in plain language, then link the source page. Curious about "Compugen executive stock transactions Form 4"? Real-time alerts show every trade, letting you track "Compugen Form 4 insider transactions real-time" before markets react. We also map pipeline disclosures in the "Compugen annual report 10-K simplified" and flag any "Compugen 8-K material events explained"—from breakthrough-therapy designations to early efficacy signals.
Whether you monitor dilution risk, compare R&D ratios, or analyze "Compugen proxy statement executive compensation", every filing type is here—10-K, 10-Q, 8-K, S-3, DEF 14A, plus "Compugen earnings report filing analysis" that links clinical milestones to numbers. Investors use these insights to spot partner-payment catalysts, gauge cash needs, and confirm insider confidence. Stop scrolling through hundreds of pages; let our AI translate Compugen’s science into actionable perspectives while you stay focused on immuno-oncology opportunities.
Compugen Ltd. entered into an amendment with MedImmune Limited, part of the AstraZeneca Group, under which it sold to AstraZeneca a portion of its existing royalty interest in the cancer immunotherapy candidate rilvegostomig for a $65 million upfront payment, due within five business days of the
The amendment also increases by $25 million the milestone payment payable to Compugen upon the next milestone, defined as the first acceptance of the Biologics License Application for rilvegostomig.
This transaction shifts part of Compugen’s expected future royalty stream into near-term cash while enhancing the potential size of a key future regulatory milestone payment linked to BLA acceptance.
Compugen Ltd. (CGEN) filed a Form 6-K
The report was signed by Eran Ben Dor, General Counsel, on November 10, 2025. Investors seeking financial details should refer to Exhibit 99.1, which contains the full Q3 2025 results.
Compugen Ltd. (CGEN) filed a Form 6-K noting it issued a press release on October 13, 2025, which is furnished as Exhibit 99.1. With the exception of the third, fourth, and fifth paragraphs of the press release, the information incorporated by reference in this report is also incorporated into the Company’s Registration Statement on Form F-3 (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on October 14, 2025.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
